UT MD ANDERSON CCOP RESEARCH BASE

UT MD ANDERSON CCOP 研究基地

• 批准号: 6151742
• 负责人: Thomas David Brown
• 金额: $ 3.17万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-09-30 至 2001-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6151742
• 关键词: 13 cis retinoate; adenocarcinoma; alternative medicine; behavioral /social science research tag; brain neoplasms; breast neoplasms; camptothecin; cancer pain; cancer prevention; cancer rehabilitation /care; cancer risk; chemoprevention; cis platinum compound; clinical research; colorectal neoplasms; community health services; cooperative study; dacarbazine; difluoromethylornithine; doxorubicin; fluorouracil; head /neck neoplasm; human subject; human therapy evaluation; interferons; ketoconazole; lung neoplasms; lymphoma; medical rehabilitation related tag; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer education; neoplasm /cancer radiation therapy; neoplasm /cancer therapy; nonHodgkin's lymphoma; oncology nursing; oral leukoplakia; prostate neoplasms; renal cell carcinoma; small cell lung cancer; tocopherols; vinblastine

UT M.D. Anderson Cancer Center proposes to continue its role as a research base in the Community Clinical Oncology Program (CCOP). The aim is to establish a national network of CCOPs by generating broad spectrum clinical protocols, encompassing both cancer control and therapeutic scientific questions, that can be implemented in a community environment and provide data of the highest quality through a solid infrastructure of data management and quality control mechanisms. M.D. Anderson Cancer Center has served as a CCOP Research Base since 1986 and has generated a full program of Phase II and Phase III treatment protocols. In the past five years, 1,416 CCOP and affiliate patients were placed on clinical trial protocols. During this period, 2,339 patients were treated on M.D. Anderson cancer control protocols. A major thrust in M. D. Anderson cancer control program is to develop programs in the areas of chemoprevention, identification of high-risk individuals, nursing research focusing on symptom management and compliance, and pain control. In order to facilitate the development of concepts and protocols in this area, major CCOP/M.D. Anderson committees have been developed, including a Chemoprevention Working Group, the Community Oncology Nurse Investigator Network, and a CCOP Pain Task Force. A major innovation has been the extension of M.D. Anderson cancer control studies in the area of lung and head and neck chemoprevention studies into the Intergroup mechanism, with participation by all major cooperative groups in these studies. In developing the clinical trial and cancer control research programs, a Data Management Core has been established with full range of data collection, and computerized data base-capabilities. A quality assurance program, including both ongoing quality control assessments and periodic on-site audits, has been developed. All CCOPs are reviewed annually for performance, and recommendations for improvement or remedial action are made as necessary. The inclusion of CCOP program in the M.D. Anderson Comprehensive Cancer Center research program has proven to be a valuable extension of the scientific mission of the Center and is now viewed as an integral part of its research capability.

UT M.D. 安德森癌症中心提议继续发挥研究作用 社区临床肿瘤学计划 (CCOP) 的基地。 目的是 通过产生广泛的频谱来建立国家 CCOP 网络 临床方案，包括癌症控制和治疗 可以在社区环境中实施的科学问题 并通过坚实的基础设施提供最高质量的数据 数据管理和质量控制机制。 医学博士安德森癌症 中心自1986年起作为CCOP研究基地，并产生了 II 期和 III 期治疗方案的完整计划。 在过去 五年来，1,416 名 CCOP 及其附属患者被安排接受临床治疗 试验方案。 在此期间，有 2,339 名患者接受了医学博士治疗。 安德森癌症控制方案。 M.D.安德森的主要推动力 癌症控制计划是在以下领域制定计划 化学预防、高危人群识别、护理研究 重点关注症状管理和依从性以及疼痛控制。 为了 促进该领域概念和协议的制定， 主要 CCOP/M.D.安德森委员会已经成立，包括 化学预防工作组、社区肿瘤学护士调查员 网络和 CCOP 疼痛工作组。 一项重大创新是 M.D. Anderson 癌症控制研究在肺癌领域的扩展 对组间机制进行头颈化学预防研究， 所有主要合作团体都参与这些研究。 在 开发临床试验和癌症控制研究计划，数据 建立管理核心，全方位数据采集， 和计算机化数据库功能。 质量保证计划， 包括持续的质量控制评估和定期的现场检查 审核，已制定。 所有 CCOP 每年都会进行审查 绩效以及改进或补救措施的建议 根据需要制作。 将 CCOP 计划纳入 M.D. Anderson 综合癌症中心研究计划已被证明是一个有价值的 该中心科学使命的延伸，现在被视为 其研究能力的一个组成部分。